Complement deficiency in pediatric-onset systemic lupus erythematosus

Abstract

BACKGROUND: Pediatric-onset systemic lupus erythematosus (pSLE) accounts for about 10%-20% of all patients with SLE. Deficiencies in early complement components of the classical pathway are the strong genetic risk factor for the development of SLE. In this study, clinical and laboratory manifestations of both complement-deficient and normal complement pSLE patients were compared.

MATERIALS AND METHODS: To investigate clinical and immunological manifestations of pSLE in Iran, 36 consecutive pSLE patients (onset before 18 years) who were followed up over a period of 2 years, were studied. Complement C1q and C2 levels were measured using radial immunodifusion assay and complement C3 and C4 levels were measured using nephelometry. Medical records were retrospectively evaluated from patient database of Children Medical Center Hospital. Data were assessed through descriptive analysis (confidence interval = 95%), paired t-test, and Pearson correlation test.

RESULTS: Twenty-one patients (58%) had at least one component of complement deficiency. Ten patients (27%) had low C1q level, 11 patients (30.5%) had low C2, nine patients (25%) had low C3, and four patients (11%) had low C4 level. Serum level of complement in pSLE was significantly lower than the control group, except C4 (P = 0.005). The low C1q patients had an earlier age of onset of disease (P < 0.0001). The cutaneous manifestations were more frequent and much more severe in pSLE with low complement (100% vs. 73%). The frequency of renal and musculoskeletal symptoms was equal, but renal morbidity was more common in pSLE with low complement. Positivity for anti-ds-DNA was less common in pSLE with low complement (71% vs. 86%).

CONCLUSION: In pSLE patients with early disease onset and more aggressive SLE manifestations and negative anti-ds-DNA test, complement deficiency should be considered.

Keywords

C1q deficiency - childhood-onset - children - complement deficiency - systemic lupus erythematosus

Publication History

Received: 02 December 2017

Accepted: 30 January 2018

Article published online:
19 February 2020

• References

• 1 Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39.
• 2 Ståhl-Hallengren C, Jönsen A, Nived O, Sturfelt G. Incidence studies of systemic lupus erythematosus in Southern Sweden: Increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 2000;27:685-91.
• 3 Kaufman DB, Laxer RM, Silverman ED, Stein L. Systemic lupus erythematosus in childhood and adolescence-the problem, epidemiology, incidence, susceptibility, genetics, and prognosis. Curr Probl Pediatr 1986;16:545-625.
• 4 Taddio A, Rossetto E, Rosé CD, Brescia AM, Bracaglia C, Cortis E, et al. Prognostic impact of atypical presentation in pediatric systemic lupus erythematosus: Results from a multicenter study. J Pediatr 2010;156:972-7.
• 5 Bowness P, Davies KA, Norsworthy PJ, Athanassiou P, Taylor-Wiedeman J, Borysiewicz LK, et al. Hereditary C1q deficiency and systemic lupus erythematosus. QJM 1994;87:455-64.
• 6 Holers VM. Complement deficiency states, disease susceptibility, and infection risk in systemic lupus erythematosus. Arthritis Rheum 1999;42:2023-5.
• 7 Bryan AR, Wu EY. Complement deficiencies in systemic lupus erythematosus. Curr Allergy Asthma Rep 2014;14:448.
• 8 Macedo AC, Isaac L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front Immunol 2016;7:55.
• 9 Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 2007;40:560-6.
• 10 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
• 11 Radice A, Sinico RA. A new oligonucleotide-based ELISA for the detection of anti-double-stranded DNA antibodies. Autoimmunity 2006;39:113-9.
• 12 Mancini G, Carbonara AO, Heremans JF. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965;2:235-54.
• 13 Jesus AA, Liphaus BL, Silva CA, Bando SY, Andrade LE, Coutinho A, et al. Complement and antibody primary immunodeficiency in juvenile systemic lupus erythematosus patients. Lupus 2011;20:1275-84.
• 14 Tahernia L, Namazi S, Rezaei N, Ziaee V. Cytokines in systemic lupus erythematosus: Their role in pathogenesis of disease and possible therapeutic opportunities. Rheumatol Res J 2016;1:e7556.
• 15 Bhattad S, Rawat A, Gupta A, Suri D, Garg R, de Boer M, et al. Early complement component deficiency in a single-centre cohort of pediatric onset lupus. J Clin Immunol 2015;35:777-85.
• 16 Al-Mayouf SM, Abanomi H, Eldali A. Impact of C1q deficiency on the severity and outcome of childhood systemic lupus erythematosus. Int J Rheum Dis 2011;14:81-5.
• 17 Karp DR. Complement and systemic lupus erythematosus. Curr Opin Rheumatol 2005;17:538-42.
• 18 Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004;22:431-56.
• 19 Trendelenburg M. Antibodies against C1q in patients with systemic lupus erythematosus. Springer Semin Immunopathol 2005;27:276-85.
• 20 Böhm I. Quantification of absolute peripheral white blood cells and their subsets in patients with lupus erythematosus: Comparison with other inflammatory diseases with and without autoimmune background. Biomed Pharmacother 2006;60:92-5.